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Background:  Rhinovirus  C  (RV-C)  is  an  important  respiratory  pathogen  of children,  but little is  known
about  its  contribution  to disease  severity,  though  viral  load  appears  to  be  important.  Difﬁculty  in  RV-C
cultivation  and  target  sequence  variation  has  precluded  the  development  of  a PCR  based  quantiﬁcation
method.
Objective:  The  aim  of  this  study  was  to develop  and  validate  reverse  transcription  quantitative  PCR  (RT-
qPCR)  assays  for  a broad  range  of  circulating  RV-C  genotypes  in  nasopharyngeal  aspirates  (NPAs).
Study  design:  Four  assays  were  designed  to quantify  a  296  bp  region  located  within  the  5′ untranslated
region  (UTR)  of RV-C  types.  These  assays  were  based  on  in  silico analysis  of  available  RV-C  sequences.
Probes  were  designed  to provide  100%  homology  to  the  corresponding  RV-C  genotypes.
4 11Results:  The  linear  dynamic  range  of  each  of the  four assays  spanned  eight  orders  of magnitude  (10 –10
copies/mL).  The  limit  of  detection  for assays  1–4 was  estimated  to  be  1147  copies/mL,  765 copies/mL,
1138  copies/mL  and  1470  copies/mL  respectively.  Each assay  demonstrated  a strong  linear  relation-
ship  (r2 =  >0.995)  and  ampliﬁcation  efﬁciency  greater  than  95%.  Repeatability  and  reproducibility  of  the
method  were  shown  to  be high,  with  coefﬁcients  of  variations  lower  than  8%  and  15%  respectively.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-NDThe assays were tested on a panel of 40 nasopharyngeal aspi-
ate samples. RV-C RNA was detected in all samples with viral load
anging from 3.3 to 9.73 log10 RNA copies/mL.
. Introduction
Rhinoviruses (RV) are a common cause of acute respiratory
nfection in people of all ages (Fawkner-Corbett et al., 2015; Puro
t al., 2005). RVs are antigenically diverse, thus people can be
nfected with different RV types over the course of a lifetime
Cooney et al., 1982, 1975). The spectrum of disease associated
ith this group of viruses can range from asymptomatic infec-
ion, mild upper respiratory tract infection (common cold) to severe
ower respiratory tract infections which may  include bronchiolitis
r pneumonia (Choi et al., 2015; Iwane et al., 2011; Luchsinger et al.,
014). RV has been identiﬁed as an important contributor to acute
sthma (Bizzintino et al., 2011) and wheezing illness in young chil-
ren is an important risk factor in the development of asthma later
n life (Jackson et al., 2008). Further, RV exacerbates pre-existing
∗ Corresponding author at: The University of Western Australia School of Pathol-
gy and Laboratory Medicine Queen Elizabeth II Medical Center Monash Avenue,
edlands WA 6009, Australia.
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ttp://dx.doi.org/10.1016/j.jviromet.2016.05.014
166-0934/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
airway diseases such as asthma, cystic ﬁbrosis and chronic obstruc-
tive pulmonary diseases (Camargo et al., 2012; Kennedy et al., 2014;
Luchsinger et al., 2014).
Genome arrangement, capsid properties and conserved
sequences are the current basis of RV species classiﬁcation, of
which there are three recognized species (RV-A, RV-B, and RV-C)
(McIntyre et al., 2013). RV-C is the most recently described species
and to date there are 55 recognised genotypes. Clinical signiﬁcance
of RV-C is still debated as some studies report that RV-C causes
more severe disease than the other two  species (Bizzintino et al.,
2011; Cox et al., 2013; Miller et al., 2009) but others have not
found this association (Iwane et al., 2011; Linsuwanon et al., 2009).
Inaccurate quantitative methods complicate the evaluation of viral
factors that may  contribute to disease severity (Schibler et al.,
2012). Viral load studies of other viruses have shown that the
amount of replicating virus is an important contributor to disease
severity (Franz et al., 2010; Jansen et al., 2010), thus an accurate
and reliable method of quantifying RV-C load may  be an impor-
tant tool in understanding the contribution of RV-C to disease
pathogenesis, disease progression and clinical management.
Conventional culture methods used to measure viral load in
clinical samples are not suitable for RV-C types as this virus is non-
cultivable using traditional techniques. Molecular methods have
overcome this problem, but the inter-genotype sequence variation
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Fig. 1. A BioEdit sequence alignment of primers and probe sequences targeted by assays one to four. Sequences of forward primer (left box), probe (centre box) and reverse
primer  (right box). Identical bases at the same position are represented by dots whereas capitalized bases indicate mismatches between sequences.
Table 1
Primers and probes used for RV-C assays.
Oligonucleotide Oligonucleotide sequence (Position)
IrlonS (Forward Primer) 5′-GCACTTCTGTTTCCCC-3′ (165–180)a
EntA (Reverse Primer) 5’-GCATTCAGGGGCCGGAG-3’ (461–445)a
RV-TYPE-C Probe 1 5′-FAM-CCTGCGTGGCTGCC-MGBNFQ-3′ (358–371)
RV-TYPE-C Probe 2 5′-FAM-CCCGCGTGGCTGCC3′-BHQ-1 (354–367)
RV-TYPE-C Probe 3 5′-FAM-CCCGCGTGGTGCCC-MGBNFQ-3′ (377–390)
RV-TYPE-C Probe 4 5′-FAM-CCTGCGTGGTGCCC3′-BHQ-
a Nucleotide position was  determined using this reference sequence [NC 002058.3] fro
Table 2
Variation in calculated copy number yield (%) of transcripts 1–4 compared to the
number of probe mismatches.
Calculated copy number of transcripts 2–4a Probe mismatches
107 106 105 104 103 102 101
Transcripts
1 100% 100% 100% 100% 100% 100% 100%
2 95% 90% 76% 72% 90% 87% 28% 1
3  <1% <1% <1% <1% <1% <1% <1% 4
4  7% 10% 12% 5% 10% 3% 3% 3
a Each RV-C transcript was tested at 7 different concentrations ranging from
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ndependent experiments) for each transcript is presented as a percentage of the
erfectly matched RV-transcript 1.
ithin the target region prevents the design of a single quantitative
ssay that quantiﬁes all genotypes at equal efﬁciencies (Schibler
t al., 2012). Furthermore, developing speciﬁc primer and probe
ombinations for each genotype would be impractical in a diag-
ostic setting. This study aims to develop and validate a minimum
et of PCR assays required to quantify circulating RV-C genotypes
ound in children.
. Materials and methods
.1. Clinical specimens
Nasopharyngeal aspirates (n = 40) were collected between June
013 and April 2015 from children presenting to the Emergency
epartment of Princess Margaret Hospital for Children in Perth.
hese samples represented a subset of children with episodic
heeze enrolled in The Prednisolone Response Evaluation in
iral Induced Episodic Wheeze (PREVIEW) study. This study was
pproved by the Princess Margaret Hospital for Children Ethics
ommittee (1970/EP).
.2. RNA extraction
Total nucleic acids were extracted from 200 L of each res-
iratory specimen using the MagMAX viral RNA isolation kit
Thermo-Fisher Scientiﬁc, Australia) according to the manufac-
urer’s instructions. Detection of the glyceraldehyde 3-phosphate
ehydrogenase (GAPDH) reference mRNA (Gueudin et al., 2003)
as utilized to ensure adequate specimen collection, RNA extrac-1 (383–396)
m GenBank. LNA bases are underlined.
tion and removal of PCR inhibitors. Good quality samples were
considered those with GAPDH quantiﬁcation cycle values (Cq) no
higher than 2 standard deviations (6.4) of the mean Cq value (25.1).
Analysis was not performed on samples above the predetermined
accepted range.
2.3. Assay design
The primers used in this study were based on previously pub-
lished primer sequences (Table 1) which amplify a 296 bp region
within the 5′ untranslated region (UTR) of RV species (Gama et al.,
1988; Ireland et al., 1993). Rhinovirus species identiﬁcation was
performed using a published semi nested PCR assay (Ireland et al.,
1993) followed by sequencing.
To select appropriate probe sequences we evaluated 204 RV-C
5′ UTR sequences which represented 34/55 of the currently known
RV-C genotypes. These sequences were obtained from our in-
house RV-C database (n = 188) and the Picornaviridae study group
website (n = 16) (http://www.picornastudygroup.com). Nucleotide
sequence alignments were analysed using BioEdit Sequence Align-
ment Editor Version 7.2.5 (Hall, 1999).
The in silico analysis of the 204 5′ UTR RV-C sequences demon-
strated that probe target region of RV-C2 (EF077280), RV-C7
(DQ875932), RV-C9 (GQ223228) and RV-C25 (JF317013) were rep-
resentative of the overall inter-genotype variation encountered in
the probe target region of the assessed RV-C genotypes. Thus, a
minimum of 4 distinct probes (Table 1) were designed to overcome
the inter-genotype variation in RV-C types. Each probe was deter-
mined to be completely homologous to the probe target region of
the representative genotypes. Probes were designed using Primer
Express v3.0 software (ThermoFisher Scientiﬁc, Australia). MGB
probes were synthesized by Applied Biosystems (ThermoFisher
Scientiﬁc, Australia) and Locked Nucleic Acid (LNA) probes were
synthesized by Sigma-Aldrich (Sigma-Aldrich, Australia).
2.4. Production and quantiﬁcation of transcribed RV-C RNA
standards
Nucleotide sequences matching the P1-P2 region of the 5′
UTR of RV-C2 (EF077280), RV-C7 (DQ875932), RV-C9 (GQ223228)
and RV-C25 (JF317013) were incorporated into individual plas-
mid  constructs manufactured by Integrated DNA Technologies (IDT,
Australia). M13  forward (5′-GTA AAA CGA CGG CCA GT-3′) and
reverse (CAG GAA ACA GCT ATG ACC) primers were used to amplify
C.T. Sikazwe et al. / Journal of Virological Methods 235 (2016) 65–72 67
F et of a
5
t
P
S
p
e
9
a
o
c
U
m
A
l
a
t
t
Sig. 2. Ampliﬁcation and standard curves generated using the primer and probe s
′UTR of RV-C genotype 2 was  used to generate the ampliﬁcation curves.
he target sequence from each individual plasmid construct. The
CR reaction mix  (20 L) contained PCR buffer (Thermo Fisher
cientiﬁc Australia Pty Ltd.), 2 mM MgCl2, 0.2 mM dNTP, 0.2 M
rimers (IDT, Australia), 0.5 U AmpliTaq Gold® (ThermoFisher Sci-
ntiﬁc, Australia) and cycling conditions were as follows: 10 min  at
5 ◦C followed by 45 cycles of 30 s at 94 ◦C, 45 s at 50 ◦C and 60 s
t 72 ◦C. Successful ampliﬁcation was conﬁrmed by the detection
f PCR products by agarose gel electrophoresis. Post PCR puriﬁ-
ation was completed using ExoSAP-It reagent (Affymetrix, Ohio,
SA) following the manufacturer’s protocol.
The Megashortscript T7 high yield transcription kit (Ther-
oFisher Scientiﬁc, Australia) was used to synthesize RNA in vitro.
ll transcription reactions were completed at 37 ◦C for 16 h fol-
owed by TURBO DNA-freeTM DNase treatment, DNAse Removal
nd MEGAclearTM Transcription Clean-Up (ThermoFisher Scien-
iﬁc, Australia) following the manufacturer’s instructions. The RNA
ranscripts were eluted in THE RNA Storage solution (ThermoFisher
cientiﬁc, Australia), and stored in single-use aliquots at −80 ◦C.ssay one. A serial 10-fold dilution of synthetic RNA transcript of a segment in the
The RNA transcript was quantiﬁed using the Qubit RNA Broad
Range assay on the Qubit 2.0 ﬂuorometer (Life Technologies, USA).
To assess the quantiﬁcation accuracy of the Qubit 2.0 ﬂuorometer
all RNA transcripts were measured in triplicate. The conversion of
RNA concentration into RNA copies/L was  done with the following
formulae:
1. M.W.  of ssRNA = (RNA transcript length (bp) × 320.5) + 159.0.
2. Number of molecules (copies) per ug ssRNA = Avogadros number
(6.022 × 1023) × (M.W.  of ssRNA).
3. RNA copies/L = [RNA transcript concentration as per
Qubit × number of molecules (copies) per ug ssRNA]/(RNA
transcript length).2.5. Quantitative real time PCR (Viral load)
The qScript XLT One-Step qRT-PCR Toughmix kit (Quanta Bio-
sciences Gaithersburg, USA) was utilized for the qRT-PCR assays.
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he 20 L reaction volume contained 8 L of template, 0.4 M of
he forward primer, 0.8 M of the reverse primer and 0.2 M of
robe (Table 1). Thermocycling conditions were as follows: 5 min
t 50 ◦C, 1 min  incubation at 95 ◦C then 40 cycles of 20 s at 95 ◦C
nd 80 s at 60 ◦C using the Rotor Gene 6000 real-time thermocycler
Qiagen, Australia). All experiments were performed in triplicate
ncluding positive controls and non-template controls. We  deter-
ined Cq values for each reaction using a manual Cq threshold of
.10 in the Rotor Gene 6000 application software.
In all experiments, a standard curve was generated by compar-
ng Cq values and the copy number. The reaction efﬁciencies of the
ssays were calculated according to the equation: E = 10(−1/M) − 1,
here M is the slope of the standard curve. The dynamic range
101–108 copies/L) of quantiﬁcation was determined by using
enfold serial dilution of RNA transcript. The RV-C load in clini-
al samples was determined by interpolation of the quantiﬁcation
ycle value into the appropriate standard curve.
.6. Analytical performance evaluation
The reliability and reproducibility of RV-C viral load quantiﬁ-
ation by RT-qPCR was assessed using the Minimum Information
or Publication of Quantitative Real-Time PCR Experiments (MIQE)
uidelines (Bustin et al., 2009). Tenfold dilutions of each cRNA
ranscript were tested in triplicate to assess intra-assay variation.
nter-assay variation of Cq values was determined by analyzing data
rom ﬁve independent assays.
Using the appropriate RNA transcript for each RV-C assay, a
enfold dilution series of twelve concentrations was  prepared. The
econd last dilution of the tenfold dilution series was  used to pre-
are a two-fold dilution series of 10 concentrations. 8 L of each
ilution from the two-fold dilution series was added to a 12 L PCR
eaction mix  and run for 50 PCR cycles using the Rotor Gene 6000
eal-time thermocycler (Qiagen, Australia). Twenty-four PCR repli-
ates were tested at each concentration. Poisson regression analysis
as used to determine the limit for a 95% conﬁdence of detection.
o evaluate variability these experiments were repeated on ﬁve
ifferent occasions.
Fig. 4. Box plots of RV-C load in samples from young children preFig. 3. The algorithm for the determination of RV-C viral load in clinical samples.
Analytical speciﬁcity was assessed using BLAST searches against
other virus families, bacteria and cell sequences from the Genbank
nucleotide collection. In addition, an in-house cross reactivity panel
was used to assess the speciﬁcity of our RV-C assays against other
respiratory pathogens.
2.7. Statistical analysis
The standard deviation (SD) and percentage coefﬁcient of vari-
ation (%CV) were used to measure intra/inter-assay variability
(repeatability and reproducibility) (SPSS v.16, IBM). SPSS (v.16, IBM,
USA) was  used for Poisson regression analysis.
senting to the Emergency Department with acute wheeze.
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Table  A1
The analytical performance of the individual PCR assays for the detection of matched RV-C RNA transcript.
RV-C Assay-1 RV-C Assay-2 RV-C Assay-3 RV-C Assay-4
Mean ± SD %CV Mean ± SD %CV Mean ± SD %CV Mean ± SD %CV
Slope −3.32 ± 0.11 3.33 −3.38 ± 0.11 3.23 −3.44 ± 0.09 2.72 −3.37 ± 0.05 1.52
Efﬁciency 0.98 ± 0.05 5.02 0.97 ± 0.05 4.68 0.95 ± 0.04 3.93 0.97 ± 0.03 3.12
Y-intercept 34.00 ± 2.46 7.23 38.00 ± 2.72 7.17 36.12 ± 1.00 7.55 33.45 ± 1.59 8.42
Goodness of ﬁt (R2) 0.999 0.11 0.999 0.47 0.999 0.09 0.999 0.08
Range  of Linearity 100–108 100–108 100–108 100–108
SD—standard deviation, % CV—percentage coefﬁcient of variation.
Table A2
A comparison of RNA transcript concentration and Cq values for the four RV-C assays.
RV-C Assay-1 RV-C Assay-2 RV-C Assay-3 RV-C Assay-4
RNA transcript concentration (copies/reaction) Mean Cq ± SD Mean Cq ± SD Mean Cq ± SD Mean Cq ± SD
100 32.77 + 0.14 33.25 + 1.48 32.66 + 0.31 31.84 + 1.01
101 29.11 + 0.12 28.22 + 0.46 29.62 + 0.06 27.37 + 0.07
102 25.86 + 0.11 25.37 + 0.06 25.95 + 0.07 24.20 + 0.14
103 22.07 + 0.06 22.25 + 0.07 22.52 + 0.04 20.96 + 0.03
104 18.68 + 0.06 18.91 + 0.06 19.08 + 0.08 17.53 + 0.10
105 15.35 + 0.04 15.39 + 0.04 15.52 + 0.11 14.20 + 0.14
106 11.73 + 0.10 13.13 + 0.11 12.05 + 0.08 10.79 + 0.04
107 8.52 + 0.04 8.78 + 0.02 8.55 + 0.02 7.81 + 0.06
108 5.27 + 0.12 5.17 + 0.20 5.19 + 0.16 4.77 + 0.07
Cq—quantiﬁcation cycle value, SD—standard deviation, Each test was  performed using RNA transcript with a primer-probe target sequence completely homologous to the
respective RV-C assay.
Table A3
Intra and Inter assay variability of the four RV-C qRT-PCR assays.
Intra-assay variationa Inter-assay variationb
RNA target and input target copies Quantity range (Calculated copies/reaction) %CV range Quantity Mean (Calculated copies/reaction) %CV
RV-C transcript-1 106 3030000–3560000 0.16–2.39 3480000 6.89
RV-C  transcript-1 104 30000–36700 0.27–2.33 37500 5.67
RV-C  transcript-1 102 125–409 0.16–7.07 361 8.92
RV-C  transcript-1 101 21–40 2.10–7.33 39 5.88
RV-C  transcript-2 106 3560000–4210000 0.22–0.61 3810000 7.50
RV-C  transcript-2 104 39100–49700 1.70–2.42 43400 10.56
RV-C  transcript-2 102 379–405 1.44–2.75 396 3.04
RV-C  transcript-2 101 35–42 3.89–5.82 39 7.22
RV-C  transcript-3 106 4080000–5790000 0.37–2.30 4760000 14.58
RV-C  transcript-3 104 35700–46200 0.23–1.23 42000 9.26
RV-C  transcript-3 102 372–470 0.40–8.58 440 9.21
RV-C  transcript-3 101 42–59 0.93–7.78 47 14.57
RV-C  transcript-4 106 4020000–4860000 0.10–1.77 4360000 8.22
RV-C  transcript-4 104 48500–52800 0.28–1.61 50000 4.89
RV-C  transcript-4 102 423–608 1.07–4.76 525 11.05
RV-C  transcript-4 101 42–49 1.47–5.16 46 5.36
%
3
3
q
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b CV—percentage coefﬁcient of variation.
a Assays were performed in triplicate.
b Five independent experiments.
. Results
.1. Validation of real-time PCR assay for RV-C viral load
uantiﬁcation
.1.1. Analytical sensitivity and speciﬁcity
We designed four assays based on RV-C 5′UTR sequences
elonging to the 34 RV-C genotypes for which 5′UTR sequences
ere available. All assays used a common primer pair, but with
ifferent speciﬁc probe sequences (Fig. 1). In silico analysis demon-
trated that the probe sequence of assay-1 was homologous to the
robe target region of 22 of the 34 RV-C genotypes, while the probe
arget region of the remaining 12 genotypes aligned completely
o the probe in either assay- 2, -3 or -4 (Table A5). These assays
ere unable to be assessed against the other 21 known genotypes
ecause the 5′UTR sequence information was unavailable.All qPCR assays were optimized for primer concentration and
annealing/extension temperature. The optimal annealing temper-
ature was determined to be 60 ◦C with a denaturation time of 20 s
and an annealing/extension time of 80 s. The PCR conditions were
selected to produce the maximum ﬂuorescent signal generated
after 40 ampliﬁcation cycles.
Serial 2-fold dilutions of 10 concentrations of each RNA tran-
script was prepared in PCR-grade water and tested to determine
the limit of detection of the assays. Using Poisson regression analy-
sis, the limit for a 95% probability of detection was estimated to be
1147 copies/mL for assay-1, and 4765 copies/mL, 1138 copies/mL
and 1470 copies/mL respectively for assays 2–4.
Nucleic acid extracts from other respiratory pathogens, includ-
ing inﬂuenza A and B, human respiratory syncytial virus, human
metapneumovirus, parainﬂuenza viruses 1–4, human adenovirus,
human bocavirus, human coronaviruses (HCoV-229E, HCoV-NL-
70 C.T. Sikazwe et al. / Journal of Virological Methods 235 (2016) 65–72
Table A4
RV-C load determinations for 40 patients enrolled in an asthma exacerbation study.
RNA copies/mL SD %CV Log10 RNA copies/mL Genotype Assay GAPDH Mean Cq GAPDH SD
9.66E + 06 1.55E + 06 0.16 6.99 C-03 1 26.64 0.4
1.35E  + 05 4.73E + 04 0.35 5.13 C-04 1 30.51 0.8
2.98E  + 08 4.47E + 07 0.15 8.47 C-06 1 24.54 0.1
5.33E  + 09 7.46E + 08 0.14 9.73 C-06 1 25.62 0.8
3.15E  + 06 8.19E + 05 0.26 6.50 C-08 2 27.71 0.6
6.44E  + 04 1.67E + 04 0.26 4.81 C-08 2 27.74 0.3
1.06E + 07 2.65E + 06 0.25 7.02 C-14 3 23.03 0.3
4.20E + 07 7.56E + 06 0.18 7.62 C-14 3 22.81 0.3
3.55E  + 06 8.17E + 05 0.23 6.55 C-14 3 28.84 0.3
5.33E  + 09 8.53E + 08 0.16 9.73 C-16 1 27.61 0.6
4.28E  + 06 1.03E + 06 0.24 6.63 C-16 1 27.72 0.2
2.96E  + 07 6.51E + 06 0.22 7.47 C-16 1 25.43 0.4
1.91E  + 08 3.44E + 07 0.18 8.28 C-16 1 27.33 0.5
1.76E  + 08 2.82E + 07 0.16 8.25 C-16 1 28.23 0.1
3.28E  + 07 6.56E + 06 0.20 7.52 C-23 1 25.61 0.3
7.53E  + 08 1.28E + 08 0.17 8.88 C-24 1 21.42 0.6
1.98E  + 06 6.73E + 05 0.34 6.30 C-25 1 25.81 0.8
5.60E + 08 8.40E + 07 0.15 8.75 C-25 1 20.22 0.5
2.28E  + 09 3.42E + 08 0.15 9.36 C-28 1 21.61 0.4
3.48E  + 05 1.08E + 05 0.31 5.54 C-30 1 27.02 0.4
1.99E  + 03 6.17E + 02 0.31 3.30 C-35 4 29.81 0.4
1.69E  + 06 6.76E + 05 0.40 6.23 C-35 4 27.32 0.4
3.19E  + 06 8.61E + 05 0.27 6.50 C-35 4 25.61 0.3
1.25E  + 07 2.13E + 06 0.17 7.10 C-35 4 22.33 1.3
3.26E + 09 5.87E + 08 0.18 9.51 C-38 1 23.71 0.5
4.45E  + 06 1.29E + 06 0.29 6.65 C-39 1 24.20 0.1
1.04E + 05 2.08E + 04 0.20 5.02 C-42 2 28.84 0.1
7.88E  + 05 2.99E + 05 0.38 5.90 C-42 2 30.04 0.8
4.15E  + 05 1.66E + 04 0.04 5.62 C-42 2 29.93 0.2
1.11E  + 06 3.66E + 05 0.33 6.05 C-43 1 28.22 0.4
2.65E  + 07 5.04E + 06 0.19 7.42 C-46 3 25.11 0.6
1.18E  + 08 1.53E + 07 0.13 8.07 C-46 3 23.53 0.2
4.73E  + 04 1.32E + 04 0.28 4.67 C-51 4 24.83 0.8
8.51E  + 08 1.62E + 08 0.19 8.93 C-04 1 27.52 0.1
1.70E + 07 3.74E + 06 0.22 7.23 C-19 4 29.81 0.1
2.93E  + 05 7.62E + 04 0.26 5.47 C-11 1 24.52 0.6
3.29E  + 05 8.23E + 04 0.25 5.52 C-11 1 28.61 0.4
1.23E  + 07 2.34E + 06 0.19 7.09 C-11 1 23.24 0.1
2.04E + 06 4.90E + 05 0.24 6.31 C-24 1 25.33 0.2
3.95E  + 03 1.46E + 03 0.37 3.60 C-13 1 24.63 0.1
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1linical samples were tested in triplicate and mean viral load calculated. SD—stand
rogenase; internal control, Cq—quantiﬁcation cycle value.
3, HCoV-OC43, and HCoV-HKU-1), Mycoplasma pneumoniae and
treptococcus pneumoniae were non-reactive in each of the RV-C
eal-time assays. In addition, a BLASTn search performed to check
he speciﬁcity of the primer and probe sets used in the assays
howed no genomic cross-reactivity with other virus families, bac-
eria or cells. However as anticipated there was cross reactivity with
ther enterovirus species.
Linearity was assessed in triplicate over ﬁve independent exper-
ments, and in all assays it spanned more than 7 orders of magnitude
Table A1). All assays demonstrated a strong linear relationship
r2 = >0.995) between Cq values and RNA copy number (Table A2).
ll assays demonstrated ampliﬁcation efﬁciencies of more than 95%
Table A1). Typical calibration and ampliﬁcation curves are shown
n Fig. 2.
.1.2. Repeatability and reproducibility
To evaluate repeatability and reproducibility of each assay, dilu-
ions (101,102,104,106) of RNA transcript were tested in triplicate.
ntra-assay %CV of the four RV-C assays ranged from 0.10% to 8.58%
nd in most cases variability increased proportionally with dilution
Table A3). Inter-assay variability was evaluated using results from
ve independent experiments and demonstrated %CV of less than
5% (Table A3).viation, %CV—coefﬁcient of variation GAPDH—Glyceraldehyde 3-phosphate dehy-
3.2. Probe mismatch
To demonstrate the need for separate assays this study exam-
ined the impact of probe-target sequence mismatches on viral
load. Each RV-C transcript was  prepared at seven different con-
centrations ranging from 107 to 101 copies/L with the calculated
copy numbers (means of three experiments) for each transcript
expressed as percentages of the copy number obtained with the
perfectly matched RV-C transcript-1. At concentrations between
107 and 102 copies/L there was minimal (<15%) difference in copy
number yield between transcript-1 and transcript-2. However, at
the lowest copy number (101), a single nucleotide mismatch (near
the 5’end) in the probe target region (Fig. 1) resulted in an inac-
curate viral load determination (Table 2). Multiple mismatches
between the probe and target (transcript-3 and-4) resulted in
substantial inaccuracy in RV-C load measurement across the con-
centration range (Table 2).
3.3. Clinical studies
An algorithm was developed to guide viral load determination
for RV-C positive samples (Fig. 3). Using this algorithm RV-C posi-
tive samples (n = 40) from children presenting with acute wheeze
were matched to the appropriate assay.
In this group of patients, a total of 23 genotypes were identiﬁed
with the most commonly detected genotypes being C-16 (n = 5), C-
C.T. Sikazwe et al. / Journal of Virologi
Table  A5
RV-C genotypes (based on 5′UTR sequences) matched to the appropriate quantiﬁ-
cation assay.
Genotype Assay
C-01 1
C-02 1
C-03 1
C-04 1
C-05 1
C-06 1
C-07 2
C-08 2
C-09 3
C-10 1
C-11 1
C-12 1
C-13 1
C-14 3
C-15 1
C-16 1
C-19 4
C-23 1
C-24 1
C-25 1
C-28 1
C-30 1
C-34 4
C-35 4
C-38 1
C-39 1
C-41 1
C-42 2
C-43 1
C-46 3
C-49 1
C-50 4
C-51 4
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5 (n = 3), C-42 (n = 3), C-14 (n = 3) and C-11 (n = 3) (Table A4). In
ilico analysis demonstrated that assay-1 aligned completely with
he target region of 24/40 (16/23 genotypes) samples. Assays 2–4
ere suitable for the remaining genotypes (n = 7) (Table A4). As
llustrated in Fig. 4, 67.5% (27/40) patients had RV-C viral loads
hat ranged between 4 and 8 log10 RNA copies/mL, 11/40 (27.5%)
atients had viral load levels higher than 8 log 10 RNA copies/mL
nd 2/40 patients (5%) had viral loads less than 4 log10 RNA
opies/mL. Overall, median RV-C load in this patient group was 6.8
og10 RNA copies/mL (IQR: 5.7-8.2 Log10 copies/mL). All samples
et  criteria for adequate sample collection and nucleic acid extrac-
ion with GAPDH Cq values within the accepted range (Table A4).
. Discussion
This study presents the development and validation of four qRT-
CR assays that, in combination are able to accurately and reliably
easure the viral load of circulating RV-C genotypes.
Reports of an association between RV-C infection and severe res-
iratory disease have been mixed as some studies have found an
ssociation (Bizzintino et al., 2011; Bochkov et al., 2011; Camargo
t al., 2012; Piralla et al., 2009) but others have not (Iwane et al.,
011; Linsuwanon et al., 2009). Similar to other acute viral res-
iratory tract infections where a correlation exists between viral
oad and disease severity (DeVincenzo et al., 2010; Li et al., 2010;
oussy et al., 2014; To et al., 2010), it is suspected that RV-C load
ay  also drive disease severity. Inaccurate quantitative methodsomplicate the evaluation of viral factors that may  contribute to
isease severity (Schibler et al., 2012). Previously published quan-
itative assays have tried to address the genetic heterogeneity of
V-C by either using an intercalating dye in place of a speciﬁccal Methods 235 (2016) 65–72 71
hydrolysis probe or adding degenerate bases in either the primer or
probe sequence (Bochkov et al., 2011; Granados et al., 2012). How-
ever, accuracy maybe impaired since these techniques may lead to
non-speciﬁc ampliﬁcation and reduced ampliﬁcation efﬁciencies
of the assays (Chemidlin Prevost-Boure et al., 2011; Schibler et al.,
2012).
In this study, performance evaluation of each assay was con-
ducted in accordance with the MIQE guidelines (Bustin et al., 2009).
A portion in the 5′UTR was chosen as a target for our assays since
previous work has demonstrated that 5′UTR sequence can be used
for RV-C genotypic assignment at almost identical accuracy to the
VP4/VP2 and VP1 and with superior clinical sensitivity (Lee et al.,
2012). All assays demonstrated a broad dynamic range, high sensi-
tivity, efﬁciency and performance in RV-C viral load determination
with both clinical samples and in vitro RNA transcripts. Viral load
in our respiratory samples were within the 1 × 103 and 1 × 1012
copies/mL range which is in concordance with previous publica-
tions (Li et al., 2010; Roussy et al., 2014; Schibler et al., 2012). All
assays demonstrated high repeatability and reproducibility with
CV of below 8% and 15% respectively. All assays were nonreactive
with a range of other potential respiratory pathogens but cross-
reactivity with other picornavirus species requires sequencing of
the 5′UTR to conﬁrm RV-C identiﬁcation prior to quantiﬁcation.
This was  also needed to determine the appropriate primer-probe
combination.
To accurately measure viral load in clinical samples it is vital
that primers and probes are designed to match the target sequence.
Indeed, previously published studies have shown that the posi-
tioning of the mismatch is a crucial determinant of probe binding
afﬁnity (Benovoy et al., 2008; Letowski et al., 2004) which may  in
turn impact upon the accuracy of the calculated viral load. Mis-
matches throughout or near the middle of the probe target region
destabilize hybridization more than those near the ends (Letowski
et al., 2004). Another recent study demonstrated that multiple mis-
matches in the probe target region may  have a greater impact
on accuracy than a single mismatch (Randhawa et al., 2011). This
is consistent with our ﬁndings which showed that at most dilu-
tions a single probe mismatch between assay probe and transcript
material had minimal impact on accuracy but when multiple mis-
matches were present there was  a substantial effect on viral load
measurement across the dilution range. Together, these ﬁndings
demonstrate the need for multiple qRT-PCR assays to achieve accu-
rate RV-C loads for the different genotypes. However, we  were able
to show that this could be achieved with a small number of assays,
requiring only four different probes to cover the 34 genotypes with
known 5′UTR sequences. It is anticipated that these four assays will
cover more of the RV-C genotypes, but that awaits further sequence
data.
Fortunately other studies have demonstrated that while a large
proportion of RV-C genotypes circulate simultaneously in various
geographical regions worldwide they are dominated by C-1, C-2,
C-6, C-16, C17, C-18 and C43 genotypes (Lu et al., 2014; McIntyre
et al., 2013). All of these genotypes were quantiﬁed at equal efﬁ-
ciencies in this study, suggesting that our assays can be used to
accurately determine RV-C load of various genotypes from different
geographical regions as well as to properly investigate differences
in pathogenesis between RV-C genotypes. A limitation of the cur-
rent method is it cannot reveal the presence of a mixed infection
and therefore may  not be able to accurately quantify the viral load
of each genotype present.
In conclusion, this study describes a reliable and accurate PCR
based method of quantifying RV-C load in clinical samples con-
taining a wide range of RV-C genotypes. These assays will provide
a reliable tool for investigating the role of RV-C in respiratory
illness, and for evaluating the effectiveness of future antiviral
therapies.
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